Emma Walmsley, GSK CEO (Fang Zhe/Xinhua/Alamy Live News)
November 17, 2022 08:01 AM ESTUpdated 11:33 AM
Deals
Cell/Gene Tx

GSK's cell ther­a­py re­treat hits an­oth­er part­ner as drug­mak­er ex­its Im­mat­ics col­lab­o­ra­tion

Amber Tong

It turns out that GSK’s broad re­treat from cell ther­a­pies went even deep­er than it let on.

As Im­mat­ics, which scored $50 mil­lion up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times